Empaworth 25 mg is an antidiabetic medication containing Empagliflozin, which belongs to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors. It is primarily used to manage blood sugar levels and provide long-term protection for the heart and kidneys. Primary Uses Type 2 Diabetes Mellitus: It is used alongside diet and exercise to lower blood sugar in adults. It works by helping the kidneys remove excess glucose from the blood through urine. Heart Failure: It reduces the risk of cardiovascular death and hospitalisation in adults with heart failure, regardless of their ejection fraction. Chronic Kidney Disease (CKD): It helps slow the progression of kidney damage and reduces the risk of reaching end-stage renal disease. Cardiovascular Risk Reduction: It is used to lower the risk of major cardiac events, such as heart attack or stroke, in adults with type 2 diabetes who also have established heart disease.